Radiopharmaceuticals

Global Radiopharmaceuticals Market to Reach US$14.3 Billion by 2030

The global market for Radiopharmaceuticals estimated at US$7.6 Billion in the year 2024, is expected to reach US$14.3 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$6.9 Billion by the end of the analysis period. Growth in the Cardiology segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 13.9% CAGR

The Radiopharmaceuticals market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.0% CAGR.

Global Radiopharmaceuticals Market - Key Trends & Drivers Summarized

How Are Radiopharmaceuticals Revolutionizing Medical Imaging and Therapy?

Radiopharmaceuticals are transforming the field of medical imaging and therapy, providing advanced diagnostic and treatment options for various diseases, including cancer and cardiovascular conditions. These radioactive compounds are used in nuclear medicine to visualize, diagnose, and treat illnesses at the molecular level. Techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) rely on radiopharmaceuticals to provide detailed images of the body`s internal structures and functions. The precision and efficacy of radiopharmaceuticals enable early detection and targeted treatment, improving patient outcomes and reducing side effects compared to conventional therapies.

What Are the Technological and Regulatory Advances in Radiopharmaceuticals?

Technological advancements are significantly enhancing the development and application of radiopharmaceuticals. Innovations in radiochemistry and radiolabeling techniques are enabling the creation of more specific and effective compounds for various diagnostic and therapeutic applications. Advances in imaging technology, such as hybrid PET/MRI and PET/CT systems, are improving the accuracy and resolution of medical imaging. Regulatory frameworks are also evolving to support the safe and efficient development of radiopharmaceuticals. Agencies like the FDA and EMA are establishing guidelines and expedited pathways for the approval of novel radiopharmaceuticals, ensuring timely access to these cutting-edge medical treatments.

How Are Radiopharmaceuticals Impacting Oncology and Cardiology?

In oncology, radiopharmaceuticals are playing a crucial role in both diagnosis and therapy. They enable the detection of tumors at an early stage and monitor the effectiveness of treatment. Therapeutic radiopharmaceuticals, such as radiolabeled monoclonal antibodies, are used to deliver targeted radiation to cancer cells, minimizing damage to surrounding healthy tissue. In cardiology, radiopharmaceuticals are used to assess myocardial perfusion and viability, aiding in the diagnosis and management of coronary artery disease and other cardiac conditions. The ability to obtain precise diagnostic information and deliver targeted therapy is revolutionizing the management of these critical diseases.

What Factors Are Driving the Growth in the Radiopharmaceuticals Market?

The growth in the radiopharmaceuticals market is driven by several factors. The increasing prevalence of cancer and cardiovascular diseases is a major driver, as these conditions require advanced diagnostic and therapeutic solutions. Technological advancements in imaging and radiopharmaceutical development are enhancing the accuracy and efficacy of nuclear medicine procedures. Regulatory support and streamlined approval processes are facilitating the introduction of new radiopharmaceuticals. The growing adoption of personalized medicine is also boosting demand, as radiopharmaceuticals can be tailored to individual patient needs. Additionally, increasing investments in nuclear medicine research and the expansion of healthcare infrastructure are contributing to market growth. These factors collectively ensure the sustained growth and innovation in the radiopharmaceuticals market.

SCOPE OF STUDY:

The report analyzes the Radiopharmaceuticals market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters, Other Product Types); Application (Oncology, Cardiology, Endocrine Tumor, Neurology, Other Applications); End-Use (Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 141 Featured) -

• Actinium Pharmaceuticals, Inc.
• Advanced Accelerator Applications
• Alliance Medical Ltd.
• Bayer HealthCare Pharmaceuticals
• Bracco Diagnostics, Inc.
• Cardinal Health, Inc.
• Curium US LLC
• GE Healthcare
• IBA Radiopharma Solutions
• Jubilant DraxImage Inc.
• Lantheus Medical Imaging Inc.
• Medi-Radiopharma Ltd.
• Nordion Inc.
• Radiopharm Theranostics Ltd.
• Siemens Healthcare GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.